News & Updates

A meta-analysis has shown the efficacy of the antifibrotic agent pirfenidone in preventing the onset and/or progression of interstitial lung abnormalities (ILAs) caused by COVID-19.

Immunization with COVID-19 mRNA vaccines is safe and provides a small protective benefit in children aged 6‒17 years, as shown in a Spain study.

Individuals living with advanced HIV infection who received pemivibart demonstrate good tolerability, with no cases of RT-PCR-confirmed symptomatic COVID-19 reported through month 6, as shown by the results of a subgroup analysis of the CANOPY study.

Several infants born to mothers living with HIV die within 50 weeks, and some of the factors that may contribute to infant death include lower maternal CD4 count, higher viral load, and maternal antiretroviral (ART) regimen, among others, suggests a study presented at CROI 2026.

COVID-19 vaccination appears to be moderately effective at preventing lingering symptoms following SARS-CoV-2 infection, and this effectiveness may increase with the number of doses administered, according to a meta-analysis.